Biostar, Kangstem Expand Stem Cell Therapy Pipelines Into AD, Psoriasis
This article was originally published in PharmAsia News
Executive Summary
Biostar Group and Kangstem Biotech are expanding their stem cell therapy pipelines via additional indications and a joint development deal, marking a further expansion of South Korea’s activities in the field into the new areas of Alzheimer’s and psoriasis.